ProQR Therapeutics N.V. (PRQR)

Clinical-stage biotech with refreshed runway after the June 2026 equity financing (including Lilly participation) and minimal debt, but still substantial losses and cash burn (TTM net margin ~−228%, free-cash-flow yield ~−29%). EV/Sales appears low versus many biotech peers, yet profit-based multiples and DCF-style intrinsic value are not reliable at this stage; treat as a speculative, catalyst-driven name rather than a fundamentals-driven compounder.

Dominant catalyst is the announced first-patient dosing in the Phase 1 AX-0811 cholestatic-liver program (2026-09-09), backed by a forward-dated investor & analyst event on 2026-09-30; media delta is improving (baseline ≈ −0.40 → scoring ≈ +0.28, item-level determinate, moderate confidence) and the Red-Flag Screen is clean with no caps applied; retail chatter is indeterminate.

PRQR is in a persistent short-term downtrend: price 1.86 sits below the SMA20 (2.13), SMA50 (1.93), EMA9 (1.94), EMA21 (2.01), WMA9 (1.90), WMA21 (2.04) and DEMA14 (1.91), though it holds above the SMA200 (1.78) and TEMA14 (1.82). Momentum is negative: MACD line -0.03 is below its signal 0.02 with a declining histogram (-0.05), RSI14 38.59 is weak and falling, and Williams %R -87.50 is deep in oversold territory (bounce potential only). ADX 22.96 shows no strong directional trend. ATR14 0.12 (6.45% of price) provides range, but the decisive blockers are liquidity: 20-day average dollar volume is only $1,919,322 vs the $5.0M floor, and the recent 3-session regular-session average is ~$1,231,061 vs the $1.5M recent-liquidity floor. This is a bounce-only, thinly-traded chart (score 2), not a tradeable swing setup.